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Abstract 
+DVKLPRWR¶V WK\URLGLWLV +7 LV SDrt of a spectrum of thyroid autoimmune conditions and this 
review provides an update on the latest development in the field. HT has a genetic predisposition 
with a number of immune-related and thyroid-specific genes conferring disease susceptibility. 
However, disentangling genes with protective and predisposing effect is a complex process that 
requires further work. The recent increase in the incidence of HT implicates environmental factors 
in disease pathogenesis including improved hygiene, increased dietary iodine intake, new 
treatment modalities and chemical agents. Additional unmodifiable predisposing factors include 
stress, climate, age and gender.  
 
Both cellular and humoral immunity play a role in HT pathogenesis. Defects in T regulatory cells 
and increased activation of follicular helper T cells may have a role in disease 
initiation/perpetuation. Infiltrating lymphocytes can be directly cytotoxic to thyroid follicular cells 
(TFC) or may affect cell viability/function indirectly through cytokine production, which alters TFC 
integrity and modulates their metabolic and immune function. Thyroid peroxidase and 
thyroglobulin antibodies are present in the majority of HT patients and help with management 
decisions. Antibodies against the sodium iodide symporter and pendrin are present in a minority 
with little known about their clinical relevance. In addition to immune cells, recent work identified 
DNA fragments, generated following cell death, and micro RNA as potential factors in HT 
pathogenesis. Despite the large number of studies, the mechanistic pathways in HT are still not 
fully understood and further work is required to enhance our knowledge and identify novel 
preventative and therapeutic clinical targets.  
 
 
 
 
 
 
 
 
 
 
Key words:  autoimmune hypothyroidism; immunogenetics; environmental factors; 
immunopathogenesis; thyroid autoantibodies 
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Introduction 
+DVKLPRWR¶VWK\URLGLWLV+7 sensu stricto is the occurrence of what was originally termed struma 
lymphomatosa, translated into English as lymphadenoid goitre, by Hakaru Hashimoto over 100 
years ago [1, 2]. These early observations were obviously made at a time when thyroid function 
testing was unavailable, immunology was nascent and the disease was judged to be rare. As is 
now clear, HT is part of a spectrum of autoimmune diseases which affect the thyroid, ranging 
from typically self-limiting forms such as focal, silent and juvenile thyroiditis through to atrophic 
thyroiditis presenting as hypothyroidism without goitre. There has been considerable speculation 
as to the exact relationship between these entities; suffice here to say that good ultrasound 
evidence shows that there is a unimodal distribution of thyroid size in hypothyroidism, which 
indicates that HT is likely to be an extreme in this distribution and does not constitute a separate 
disease entity, although there are different clinical presentations across the distribution curve [3]. 
And while immunological techniques described below are defining discrete types of disease, such 
the IgG4-related variant, for the purposes of this review we will not distinguish HT from other 
forms of autommune hypothyroidism except where indicated; this pragmatic approach is also 
necessary because of the rather loose definition that investigators apply to patients. There have 
been several recent reviews of this subject, in large part occasioned by the centenary of 
+DVKLPRWR¶VGLVFRYHU\ [4-7]. We therefore have mainly concentrated on papers since 2010, to 
bring readers an update on recent developments in the field, focussing firstly on predisposing 
factors and then on the pathogenic mechanisms responsible for tissue damage. 
 
Genetic susceptibility 
Recent studies on susceptibility to HT have revealed several new aspects of interest. Using the 
diagnosis data set for military personnel in the USA, it has been established that HT has the 
highest incidence in white individuals, and is lowest in black and Asian/Pacific Islander individuals 
[8]. This difference may be the result of genetic and/or environmental factors, yet the pattern is 
reversHGLQ*UDYHV¶GLVHDVH (GD), which shares some of these susceptibility factors; unravelling 
what causes these striking ethnic patterns would be a novel approach to understanding 
susceptibility. A related phenomenon is the differential clustering of additional autoimmune 
diseases that are associated with GD and HT; HT is markedly more associated with such 
GLVRUGHUVHVSHFLDOO\$GGLVRQ¶VGLVHDVHDQGW\SHGLDEHWHVPHOOLWXV [9]. Again this could be the 
result of genetic and/or environmental factors.  
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A genetic susceptibility to the inheritance of thyroid autoantibody patterns has been established 
and the familial aggregation of thyroid autoantibodies is clearly shown in a recent study of 
multiplex Han Chinese families [10].  Work on monozygotic twins discordant for HT has 
demonstrated that in the absence of thyroid disease, these individuals nonetheless share a 
higher than expected propensity to develop thyroid peroxidase (TPO) autoantibodies that 
recognise one of the two main epitopes on this autoantigen [11]. The technique of regression of 
offspring on mid-parent screening has been used to show that IgG4 subclass thyroid 
autoantibodies display heritability, albeit only in those with high levels of both TPO and 
thyroglobulin (TG) antibodies, and this could allow the development of novel screening methods 
to predict disease evolution [12].  
 
Whilst more attention has been paid to GD with regard to finding the responsible genes, there are 
an increasing number of attempts to investigate HT using either the candidate gene approach or 
genome wide association studies (GWAS). These genes can be broadly classified into those 
which control the immune response and those which are thyroid-specific and thus increase target 
organ risk. Amongst the first group, further work has been done on the archetypal immune 
response genes encoded on the HLA complex, which has revealed that HLA-B*46:01 confers an 
increased risk of HT developing in Han Chinese children, using a combined case-control and 
family-based approach [13].  Using a sample of 444 Japanese HT patients, HLA-A*02:07 and 
HLA-DRB4 conferred susceptibility and the HLA-A*33:03-C*14:03-B*44:03-DRB1*13:02-
DQB1*06:04-DPB1*04:01 haplotype conferred protection [14]. A smaller scale case control study 
of 75 Caucasian HT patients found that HLA-A2 did not confer protection against disease, in 
contrast to GD [15]. These results highlight the complexities of studying even a single set of 
genes, with both protective and susceptibility actions that may be in part epistatic [14] and which 
have ethnically restricted effects.  
 
The involvement in autoimmunity of many other immunoregulatory genes besides those in the 
HLA complex is now clear; amongst these, single nucleotide polymorphisms (SNPs) in CTLA-4, 
PTPN22, CD40 and IL2R are known to have some effect in both GD and HT and more 
information has come from meta-analyses. A recent meta-analysis of the A49G SNP in CTLA-4 
has shown that this increases the risk of HT in both East Asian and white individuals, with odds 
ratios of 1.48 and 1.27 respectively [16]. By contrast, a meta-analysis of studies on the PTPN22 
C1858T polymorphism found no association with HT, although this was associated with GD [17]. 
The situation is similar with the CD40 C/T1 polymorphism, which is associated with susceptibility 
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to GD but not HT [18]. The latter study raises the question of how to classify controls with high 
levels of thyroid autoantibodies; we do not agree with the conclusion that these individuals should 
be classified as having HT, especially given the independent heredity of such antibodies. 
 
Polymorphisms in the genes which encode or regulate cytokines constitute another obvious set 
of candidates for testing, although results to date have been inconclusive. The largest study 
recently (of 202 Tunisian HT patients) found an association with an IL1RN VNTR polymorphism 
[19] and a study with a similarly sized population of 182 Chinese HT patients has shown that the 
rs763780 polymorphism in IL17F, but not the three studied SNPs in the IL17A gene, may also be 
associated with HT [20]. In a small scale study that was however replicated across three 
separate populations, the rs6887695 IL12B variant was more frequent in GD and less frequent in 
HT, compared to controls [21]. Another study of 108 Japanese HT patients, subdivided into mild 
and severe forms, has identified a borderline association with a SNP in IL6 in severe HT, but this 
study is compromised by the multiple uncorrected comparisons and small size [22]. The same 
group, using a similar sized sample, have also reported associations of a SNP in GITR with mild 
rather than severe HT; this finding is somewhat supported by the identification of a higher 
proportion of glucocorticoid-induced tumour necrosis factor-receptor (GITR)-expressing T cells in 
HT individuals with the GG genotype of the SNP [23]. Such T cells may have regulatory and 
effector functions. The STAT family of proteins are transcription activators that regulate a number 
of immunoregulatory pathways, including cytokine signalling.  Using a population of 250 Chinese 
HT patients, a SNP in STAT3 was found to be associated with HT, as well as GD [24].  
 
With respect to thyroid-specific genes, it has been established that polymorphisms in the gene 
encoding the TSH receptor confer susceptibility to GD but not HT, whereas polymorphisms in TG 
appear to confer more general susceptibility to thyroid autoimmunity. Five polymorphisms in TG 
have been associated with GD rather than HT in a recent Japanese cohort of patients, leading to 
identification of a putative protective haplotype for the former [25]. Attempts have also been made 
to understand how polymorphisms in TG may be implicated in pathogenesis; at least one 
possibility is that a disease-associated SNP in the promoter confers increased activity, but only in 
the presence of interferon, which is clearly of interest given the effects of this agent 
therapeutically, as described below [26]. Although not thyroid-specific in tissue location, 
selenoproteins (SEP) are central to thyroid hormone deiodination and selenium itself may have a 
role in predisposition as a dietary environmental factor (see below).  In a study of 481 HT patients 
from Portugal, there was a significant association with a promoter SNP in SEPS1, giving an odds 
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ratio of 2.24 [27]. Of the candidate gene studies just mentioned, this is by far the largest and the 
most likely therefore to have sufficient power to be reliable, but as with all the others, replication 
is required, a task compounded if consideration is taken of possible heterogeneity conferred by 
sex, ethnic background or disease subtype. As with other polymorphisms that may be relevant, 
epistatic effects and an interaction with environmental factors, in this case selenium intake, 
increase the complexity of analysis. 
 
GWAS offers a hypothesis-free approach to understanding disease susceptibility which allows 
the discovery of novel pathways, although these studies have their own particular issues [28]. 
One good example is the uncovering of a new set of genetic markers, including polymorphism in 
MAGI3, which are associated with an increased risk of progression from TPO antibody positivity 
to hypothyroidism [29]. Using a custom-made SNP array to analyse over 100,000 common SNPs 
in 462 British HT patients, 4 definite new associations were found (7 when the sample was added 
to a larger JURXSRI*UDYHV¶SDWLHQWV; these loci have been associated with other autoimmune 
disorders [30]. Another refinement has been to undertake detailed fine mapping of a locus 
previously linked to HT on chromosome 10q; this revealed an association with ARID5B, which 
has also been associated with rheumatoid arthritis and GD in Japanese patients [31].  
 
A summary of current studies is provided in Table 1. It is clear that the genetics of HT are much 
more complex than previously thought and that a detailed understanding will only be gained 
slowly through adequately powered and replicated datasets. Association is not causation, and 
more work is needed to understand how certain SNPs exert their effect, how they might interact 
with one another through epistasis and how they also interact with environmental factors.  
 
Environmental contribution 
The importance of a direct or epigenetic role for environmental factors in the pathogenesis of HT 
is clear from the recent changes in epidemiology. A detailed analysis of the pathological 
specimens at the Johns Hopkins Hospital over the last century has revealed that HT was rare 
before the 1950s but it is now one of the commonest autoimmune disorders [32]. A survey from 
Austria of thyroidectomy specimens from 1979 to 2009 supports these data by showing an 
increase in HT over the last 31 years [33]. Such rapid changes clearly cannot be the result of any 
shift in genetic susceptibility, but a number of obvious environmental suspects have changed with 
sufficient rapidity to be credible candidates for this increase. Foremost amongst these are (i) the 
shift towards a more hygienic environment, which may skew the developing immune system 
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away from microbial responses towards the development of allergic and autoimmune diseases, 
including those against the thyroid (reviewed in [34]), and (ii) an increase in dietary iodine. Many 
previous studies have demonstrated that excessive dietary iodine can precipitate or exacerbate 
HT in susceptible individuals and this information continues to be gathered. For instance a 15 
year follow-up of the Pescopagano survey, which has monitored the effects of voluntary iodine 
prophylaxis in an iodine-deficient part of Italy, has shown that the prevalence of thyroid 
autoantibodies almost doubled and HT quadrupled during this time [35].  
 
There are also epidemiological data suggesting that inadequate dietary selenium intake may 
exacerbate HT; selenium intake is geographically variable and in Europe has fallen by 50% over 
the last three decades. However a recent meta-analysis of trials of selenium supplementation in 
HT showed no clear beneficial effect on thyroid morphology, although TPO autoantibody levels 
do fall over 3 months [36]. A Cochrane Systematic Review has come to much the same 
conclusion, with evidence that current studies are inadequate to assess any benefit [37]. The 
CATALYST trial is now under way which may answer questions about a role for selenium in 
thyroid autoimmune disease decisively [37a]. A final dietary component which has created 
interest is vitamin D, albeit with a major contribution to serum levels being due to sun exposure. 
Although there is some evidence of lower serum vitamin D levels in individuals with HT, these 
changes may be the result of the metabolic changes of hypothyroidism as much as any 
aetiological effect, especially as the levels of vitamin D tend to be inversely related to the severity 
of thyroid dysfunction [38]. A recent review has examined this topic in depth, drawing attention to 
the limitations of previous studies of vitamin D in HT which should be addressed in any future 
studies [38a]. 
 
Treatment of patients with novel anticancer treatments, such as cytokines like interferon-Į and 
tyrosine kinase inhibitors, can also induce transient or permanent thyroid dysfunction, including 
HT; a comprehensive review of this topic has recently been published [39]. To examine the 
possibility that HT induced by interferon-Į could operate through a distinct background genotype, 
a genomic convergence approach has been used, combining genetic association data with 
transcriptome analysis of interferon-regulated genes: this led to the identification of 3 putative 
loci, HLA, SP100/110/140 (on chromosome 2q37.1) and TAP1 (on chromosome 6p21.3) which 
might be involved [40].  The immune reconstitution syndrome arises during the reconstitution 
phase after any type of lymphocyte depletion and may result in autoimmunity. When this affects 
the thyroid, it normally results in GD, as seen with alemtuzumab therapy in multiple sclerosis and 
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the reversal of the lymphopenia of HIV infection with highly active antiretroviral therapy [41]. 
Alemtuzumab therapy does however result in hypothyroidism in 7% of treated patients and is 
accompanied by TSH receptor antibodies (presumably functional blockers) in three-quarters of 
these cases [42]. There is also a single case report of painful HT arising after reconstitution in an 
HIV-infected individual receiving highly active antiretroviral therapy [43]. 
 
Smoking is associated with an increased risk of GD and especially ophthalmopathy, but generally 
conflicting results have been reported on any association with HT. A detailed population-based, 
case-control study has recently found that smoking cessation is associated with a sudden and 
transient rise in HT [44], while a study of individuals genetically at risk of HT has shown that 
progression to overt hypothyroidism is less common in current smokers [45].  Moderate alcohol 
consumption also turns out to be protective, based on similar types of analysis [46, 47], and this 
is a feature shared with other autoimmune disorders like rheumatoid arthritis. However the exact 
immunological basis for these protective effects of smoking and drinking remain to be elucidated. 
 
Infection has for decades been examined as a possible aetiological factor in thyroid 
autoimmunity. There is evidence that hepatitis C virus may precipitate HT, and permanent 
hypothyroidism occurs in around 15% of patients who have had subacute viral thyroiditis; some 
of these may have an autoimmune basis. Attempts to find viruses in thyroid material in HT have 
generally failed to be replicated. A recent such candidate is HHV-6 which appears to be active 
rather than latent when detected in patient with HT and shows tropism for thyroid follicular cells 
(TFC); these studies used relatively small numbers of patients and controls (62 in total) and 
clearly more work is needed before drawing any conclusions [48]. Another frequently studies 
candidate is Yersinia infection which has been associated in some studies with the development 
RI*UDYHV¶GLVHDVHLQSDUWLFXODU$UHFHQWprospective study of 790 relatives of probands at risk of 
thyroid autoimmunity found no evidence to support a role for Yersinia in the development of 
thyroid antibodies over a 4 year period [48a] Much less attention has been paid to environmental 
toxins as agents that could explain the rapid change in prevalence of HT but two recent 
epidemiological studies, one showing an increase in HT in those living near a petrochemical 
complex, and another showing an increase in hypothyroidism (HT not specifically identified) in 
those exposed to pesticides, show the potential of such compounds [49, 50]. A summary of the 
environmental factors associated with HT is shown in Table 2. 
 
Existential factors 
Formatted: Font: Italic
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As well as the susceptibility conferred by genes and the environment, another set of factors 
influence the predisposition to thyroid disease; we have labelled these as existential [5], in that 
they are an intrinsic and unavoidable part of human existence. Thus getting older increases the 
risk of HT, until the extremes of old age, and being female is the biggest risk factor currently 
known, as women develop HT up to 10 times more frequently than men. This strong female 
association remains unexplained although our hunch is that sex steroids have the critical role, as 
there is compelling evidence for such effects in animal models of many types of autoimmunity 
[51]. Alternative explanations include skewed X chromosome inactivation (away from the 
expected 50:50 parent of origin ratio) and fetal microchimerism [51a]. A recent survey of 490 
patients with HT found no significant difference in the inactivation of X chromosomes from 
normal, but when combined with 4 other studies in a meta-analysis, results just reached 
significance, suggesting that skewing may have some role (P<0.03) [52].  Results were much 
more convincing for GD. A small study of 7 HT patieQWV DQG  *UDYHV¶ SDWLHQWV KDV IRXQG D
significantly higher number of circulating fetal lymphocytes than in 10 healthy controls, but there 
ZDVDOVRDVLJQLILFDQWO\KLJKHUQXPEHULQWKH*UDYHV¶SDWLHQWVFRPSDUHGWR+7SDWLHQWV[53].   
 
If microchimerism is indeed important, it would seem reasonable to expect that HT would be 
more frequent in women with a higher number of pregnancies. Advancing parity has been 
associated with an increased risk of becoming TPO autoantibody-positive [54], although this 
study did not establish whether this was accompanied by HT itself. A survey of 4.6 million Danes 
for whom childbirth records were available has looked at hospitalisation records and found a 
slight overall increase in autoimmune diseases in those who had been pregnant, compared to 
women without children, with a relative risk of 1.04 [55]. There was a possible specific 
association with HT with a relative risk of 1.11 (confidence interval 1.00-1.24). However, there 
was only a significant effect in those women who had a single child rather than more children, 
and the effect was also only significant within 4 years of the birth of the most recent child. Despite 
the limitations of this study, notably in the ascertainment of cases through hospitalisation with all 
of its implications, these data indicate to us that any effect of parity (and hence microchimerism) 
in HT is likely to be rather must be very limited, and the results could just as readily be the result 
of the well-known post-partum exacerbation of autoimmune thyroiditis, which has its origins in 
pregnancy-induced alterations in maternal T cell regulation [56].  
 
Stress has been associated with GD but there is no evidence that it plays a role in progression to 
HT in predisposed individuals [57]. Seasonal effects have been examined, although these may 
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be related to environmental influences such as infection. A recent study found no consistent 
impact of month of birth in predisposition to HT [58]. Climate may have an effect on 
predisposition; preliminary findings show that Yakut women living in Siberia have a higher than 
expected prevalence of TPO autoantibodies [59]. The problems of global climate change might 
therefore include effects on autoimmunity in the future.  
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Pathogenic mechanisms 
Autoimmune thyroid disease is characterised by lymphoid infiltration of the thyroid gland including 
T and B cells. Therefore, both cellular and humoral immunity have a role in the pathogenesis of 
thyroid autoimmunity. 
 
Cellular immunity 
In autoimmune thyroid disease, T cells migrate from the periphery into the thyroid gland and 
actively participate in the autoimmune process. The main cellular pathways that contribute to 
thyroid destruction are discussed with special focus on latest developments in the field. 
  
Suppressor and regulatory T cell defects 
Suppressor T cells were initially considered to be specific CD8+ cells tasked with inhibiting 
unwanted immune responses. Early work demonstrated defects in T suppressor cell response to 
thyroid-specific antigens in autoimmune hypothyroidism, implicating antigen-specific T 
suppressor failure in disease pathogenesis [60]. However, findings were criticised for the non-
physiological experimental conditions and poor reproducibility of data, casting doubts on the 
importance of this putative pathway in disease pathogenesis. Some of the functions of 
suppressor T cells now appear to be those of regulatory T cells (Tregs) which represent 5-10% of 
CD4+ cells [61]. Natural Tregs are characterised by high level of CD25 expression as well as 
expression of transcription factor Foxp3 [62, 63]. These cells can dampen the immune response 
through direct cell to cell contact or indirectly through the production of cytokines such as 
transforming growth factor (TGF)-ȕ and interleukin (IL)-10 [64, 65]. Although some studies have 
shown altered Treg numbers or function in autoimmune thyroid disease (ATD), data have been 
inconsistent [66-69]. More recent work in 7 GD and 13 HT patients has convincingly 
demonstrated altered Tregs activity in ATD compared with healthy controls (n=9) or individuals 
ZLWK'RZQ¶VV\QGURPHQ  a condition with known autoimmune predisposition [70]. Therefore, 
better understanding of the role of Tregs in the development of thyroid autoimmunity may allow 
early identification of individuals at risk and may even establish novel therapeutic targets.  
Another potential mechanism for the development of HT is decreased sensitivity of CD4+ T cells 
WR WKH LQKLELWRU\ HIIHFW RI 7*)ȕ 8VLQJ SHULSKHUDO EORRG FHOOV 0LUDQGROD DQG FROOHDJXHV
GHPRQVWUDWHG LQFUHDVHG SURWHLQ NLQDVH &İ H[SUHVVLRQ LQ &'+ cells, which is responsible for 
enhanced survival and activity of these cells, secondary to diminished response to 7*)ȕ 
inhibition [71]. 
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Follicular helper T cells 
Follicular helper T cells (Tfh) are a relatively newly identified subset of T helper cells, involved in 
promoting antigen-specific B cells through the production of IL-21 [72]. These cells express 
chemokine receptor CXCR5 together with inducible costimulator (ICOS) protein, which 
represents one of the molecules required for normal cellular function. Using flow cytometry, Zhu 
and colleagues [73] have shown increased Tfh cells in the peripheral blood of HT patients, which 
correlated with thyroid-specific antibody levels. Moreover, CD4+CXCR5+ICOShigh cells were found 
in HT thyroid tissue, further implicating these cells in disease pathogenesis.  
 
Cytotoxicity and apoptosis 
CD8+ T cells against both TPO and TG are detected in patients with ATD and mediate gland 
destruction [74]. However, only 2-3% of infiltrating CD8+ cells recognise TPO/TG, suggesting the 
majority of these cells are not thyroid autoantigen-specific. This is not unprecedented as similar 
data have been reported in type 1 diabetes, another organ-specific autoimmune condition [75].  
In addition to cytotoxicity, early reports implicated apoptosis in causing tissue destruction in 
autoimmune hypothyroidism [76].  Increased expression of the apoptotic molecule Fas is evident 
on TFC from HT tissue samples, and in vitro studies demonstrate enhanced Fas expression by 
cytokines but inhibition by TSH [77]. Indeed, the detection of apoptotic cell markers in HT tissue 
samples, including upregulation of caspase-3 and decreased expression of bcl-2, further 
supports the role for apoptosis in disease pathology [78].  More recent work has shown that pro-
inflammatory cytokines are not only responsible for disruption of thyroid hormone synthesis but 
can mediate apoptosis of thyroid follicular cells through increased oxidative stress [79].   
 
Humoral immunity 
Thyroid-specific antibody production is a key feature of ATD. We briefly summarise the main 
thyroid antibodies with the most recent developments in this area. 
 
TPO/TG antibodies and immunoglobulin subclass 
Antibodies against TG and TPO are present in almost all patients with HT [80]. In addition to aiding 
the diagnosis, TPO antibodies can be used to help predict development of hypothyroidism, 
particularly when combined with measurement of TSH levels [81].  
IgG4-related sclerosing autoimmune disease was first reported more than a decade ago [82] and is 
characterised by significant organ infiltration of IgG4-positive plasma cells. A number of groups have 
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recently documented a distinct variant of HT where the thyroid gland is infiltrated with IgG4-positive 
cells. Histologically, IgG4-positive glands showed higher grade fibrosis and more widespread 
follicular cell degeneration compared with non-IgG4 thyroiditis. Clinical differences were also 
documented, as IgG4 positivity was associated with male gender, rapid progress of hypothyroidism, 
more diffuse low echogenicity of the thyroid gland and higher antibody levels [83, 84]. In support of 
the relationship between thyroid fibrosis and IgG4, other investigators found Riedel¶VWK\URLGLWLVWREH
part of systemic IgG4 disease spectrum, although only a small number of patients were analysed 
and further studies are warranted to confirm these findings [85].  
 
Sodium iodide symporter (NIS) and pendrin antibodies 
The NIS mediates iodine uptake by the thyroid gland, while pendrin is responsible for the efflux of 
iodine through TFCs. NIS antibodies are found in 17-31% of patients with ATD and in some cases 
these antibodies have a functional role in vitro by inhibiting the activity of the symporter [86-89].   
Antibodies against pendrin are detected in only 9-11% of patients with ATD [86, 87]. Although the 
frequency of NIS and pendrin antibodies is slightly lower in HT compared with GD, the marginal 
difference indicates that these antibodies are unlikely to determine disease presentation.  
 
Thyroid stimulating hormone receptor (TSHR) antibodies 
Antibodies against the TSHR receptor have a clear functional role in GD by stimulating receptor 
function (thyroid stimulating antibodies or TSAb). Less commonly, however, these antibodies 
possess blocking activity. The balance between TSAb and TBAb (thyroid blocking antibodies) 
can determine disease presentation (hyper- or hypothyroidism), which explains the fluctuating 
thyroid hormone levels in some patients with ATD. A number of factors can modulate the balance 
between TSAb and TBAb, including antithyroid drugs or thyroxine treatment and pregnancy [90]. 
In one unusual case reported recently, an 80 year old woman with long standing HT developed 
Graves¶ GLVHDVH, with apparently de novo synthesis of TSAb and no evidence of TBAb [90a]. 
Understanding how such freakish fluctuations in TSHR autoimmunity occur would provide useful 
insights into the pathogenesis of thyroid autoimmunity.  
 
The role of cytokines 
This topic has been previously reviewed [91, 92], and only a brief update is provided here. 
Cytokines were initially classified into those produced, in mice at least, by Th1 and Th2 T cell 
subsets, and are involved in cellular and humoral immune responses respectively. Later a third 
subset was added, called Th3 cells which mainly synthesise TGFFGȕ and act as regulatory cells 
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[65]. A more recent subset of Th17 cytokines was described, which includes IL-17 and IL-21, 
cytokines that are involved in the pathogenesis of chronic inflammatory conditions [93]. Although 
IL-22 is classified by some as a Th17 cytokine [94], others describe a distinct subpopulation of T 
helper cells that produce this cytokine, termed Th22 [95].   
 
Studies have attempted to understand the type of cytokine response in ATD and a predominance 
of a Th1 response in HT has been demonstrated [92]. However, we should be cautious in our 
interpretations as surgery is unusual in HT and could be introducing a selection bias making 
general applicability of the results uncertain. Therefore, studies on peripheral blood cytokine 
levels may be more appropriate but these have their drawbacks in terms of sensitivity and 
specificity.  
A study investigating IL-17 and IL-22 has shown increased plasma levels of these cytokines in 
ATD, particularly in patients with HT. This was associated with stronger expression of IL-17 and 
IL-22 in the thyroid gland of HT patients compared with GD or controls, suggesting a specific role 
for these cytokines in autoimmune hypothyroidism [96]. Production of IL-22 is promoted by IL-6 
and tumour necrosis factor-Į. Interestingly, peripheral T lymphocytes from HT patients show 
enhanced differentiation into Th22 cells following IL-6 stimulation in vitro. Moreover, IL-22 levels 
correlate with TPO antibody levels in patients with HT, suggesting a role for this cytokine in 
antibody production [97]. However, others have documented that IL-22 has a role in GD rather 
than HT pathogenesis [98]. Given these contradictory data further studies are warranted to clarify 
the role of IL-22 in HT. 
 
IL-23, produced by cells of the innate immune response, is part of the IL-12 family promoting a 
Th1 response. IL-23 serum levels were higher in 81 HT patients compared with 80 controls, 
although only 56% of HT patients had detectable levels of this cytokine [99]. IL-14 and IL-16 have 
also been studied, as these too are involved in humoral and cellular immune responses 
respectively. IL-14 and IL-16 gene expression was detected in almost all HT tissue samples but 
only a minority of MNG, suggesting a role for these cytokines in autoimmune hypothyroidism. 
However, the detection of IL-14 and IL-16 in GD tissue samples indicates that these cytokines 
are not HT-specific but more likely to play a role in the diverse spectrum of ATD (Kemp et al., 
manuscript under revision).  
 
In addition to the effects of cytokines on infiltrating inflammatory cells, these molecules can 
modulate thyroid cell growth and function, and can even alter the immunological properties of 
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these cells [92]. TFC integrity is compromised in HT, related, at least in part, to reduced 
expression of junction proteins, including ZO-1 and JAM-A. In vitro studies have demonstrated 
that IL-1ȕ can directly modulate junction protein expression, thus mediating TFC destruction in 
HT [100]. Cytokines can also reduce caveolin 1 production (part of the thyroxisome together with 
TPO and dual oxidase), thereby directly modulating thyroid hormone production [79].  
  
DNA fragments and micro RNA 
Previous work has shown that molecules released from dying or dead cells encourage the 
development of a sterile inflammatory milieu, which in turn activates the immune response [101]. 
More specifically, the release of genomic DNA has been shown to activate innate immunity [102]. 
In vitro thyroid cell injury and subsequent genomic DNA release was associated with the 
development of an inflammatory reaction and compromised function of key thyroid proteins 
including NIS [103]. In a series of elegant experiments, the investigators demonstrated that 
histone H2B, which bound genomic DNA, was responsible for activation of innate immunity and 
therefore sterile thyroid injury appears to be enough to trigger thyroid autoimmunity. 
 
MicroRNAs (miRNA), which are small noncoding RNA regions, have also been implicated in the 
pathogenesis of thyroid immunity. Various miRNA have been shown to control innate and 
adaptive immune responses [104]. In HT tissue, obtained using fine needle aspiration, miR-
155_2 was found to be decreased, coupled with an increase in miR-200a1 when compared with 
healthy control thyroid tissue [105]. In addition to tissue samples, serum miRNA was also tested 
with miR-22, miR-375 and miR-451 showing increased levels in both HT and GD patients 
compared with controls [106]. Further work in this area is required to understand the potential of 
miRNA as novel therapeutic targets in ATD in general and HT in particular. 
 
The pathogenic mechanisms operating in HT are summarised in Figure 1. 
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Figure Legend 
)LJXUH  6XPPDU\ RI WKH SDWKRJHQLF PHFKDQLVPV LQ +DVKLPRWR¶V WK\URLGLWLV &RPSURPLVHG
function to T regulatory (Treg) cells, increased activity of follicular helper T cells (Tfh), DNA 
fragments (frag) released following cell death and altered microRNA (miRNA) profile result in 
initiation and perpetuation of the autoimmune process. Thyroid infiltrating T and B cells result in 
cell cytotoxicity, apoptosis and antibody production. A large number of cytokines are synthesised 
by the infiltrating inflammatory cells, which further contribute to the inflammatory process and 
gland destruction.        
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